KLAC
45
3
EMN
40
5
IPG
43
3
EQIX
59
2
NI
63
5
T
32
2
ADP
57
2
NRG
32
5
MPC
28
3
AMGN
42
14
ESS
44
5
DTE
49
16
CAT
47
3
KR
50
5
CVX
25
14
CTSH
55
3
LRCX
56
4
IVZ
42
13
TGT
35
4
KHC
11
2
KLAC
45
3
EMN
40
5
IPG
43
3
EQIX
59
2
NI
63
5
T
32
2
ADP
57
2
NRG
32
5
MPC
28
3
AMGN
42
14
ESS
44
5
DTE
49
16
CAT
47
3
KR
50
5
CVX
25
14
CTSH
55
3
LRCX
56
4
IVZ
42
13
TGT
35
4
KHC
11
2
Financhill
Back

MediciNova 10K Form

Sell
34

MNOV
MediciNova

Last Price:
$2.16
Seasonality Move:
4.51%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2024-05-09 10Q MNOV/MediciNova Quarterly
2023-11-09 10Q MNOV/MediciNova Quarterly
2023-08-09 10Q MNOV/MediciNova Quarterly
2023-05-11 10Q MNOV/MediciNova Quarterly
2022-11-10 10Q MNOV/MediciNova Quarterly
2022-08-11 10Q MNOV/MediciNova Quarterly

Receive MNOV News And Ratings

See the #1 stock for the next 7 days that we like better than MNOV

MNOV Financial Statistics

Sales & Book Value

Annual Sales: $1M
Cash Flow: $-2M
Price / Cash Flow: 0
Annual Sales: $1.12
Price / Book: 1.92

Profitability

EPS (TTM): -0.21000
Net Income (TTM): $-10.3M
Gross Margin: $0
Return on Equity: 0%
Return on Assets: 0%

MediciNova Earnings Forecast

Key MediciNova Financial Ratios

  • The Selling, General & Administrative Expenses for MNOV have been equal to 524.24% of Gross Profit Margin.
  • The Research & Development expenses have been 565.79% of Revenue.
  • The Interest Expense is 0.00% of Operating Income.
  • Per Share Earnings over the last 23 years have been positive in 13 years.

MediciNova Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: MNOV
CUSIP: 58468P
Website: medicinova.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0
Quick Ratio: 0

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

MNOV Technical Analysis vs Fundamental Analysis

Sell
34
MediciNova (MNOV) is a Sell

Is MediciNova a Buy or a Sell?

  • MediciNova stock is rated a Sell
    The current MediciNova [MNOV] share price is $2.15. The Score for MNOV is 34, which is 32% below its historic median score of 50, and infers higher risk than normal.